Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTRIM 1: Intradermal IMO-2125 in pT3-4 cN0M0 Melanoma
2023-509461-20-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tilsotolimod in cutaneous melanoma (CM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Tumor-positive sentinel lymph node rate at 7 days. Planned start Dec 2024; status: authorised.
02
Drugs
tilsotolimod
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2023-509461-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509461-20-00.